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Routine use of vancomycin for perioperative prophylaxis is discouraged,
principally to minimize microbial resistance to it. However, outcomes and
costs of this recommendation have not been assessed. We used decision-
analytic models to compare clinical results and cost-effectiveness of no pro-
phylaxis, cefazolin, and vancomycin, in coronary artery bypass graft sur-
gery. In the base case, vancomycin resulted in 7% fewer surgical site
infections and 1% lower all-cause mortality and saved $117 per procedure,
compared with cefazolin. Cefazolin, in turn, resulted in substantially fewer
infections and deaths and lower costs than no prophylaxis. We conclude
that perioperative antibiotic prophylaxis with vancomycin is usually more
effective and less expensive than cefazolin. Data on vancomycin’s impact
on resistance are needed to quantify the trade-off between individual
patients' improved clinical outcomes and lower costs and the future long-
term consequences to society.
The emergence of vancomycin-resistant enterococci has
opened a new era of hardly treatable bacterial infections,
and there is now evidence that more virulent common patho-
gens such as Staphylococcus aureus can also develop resis-
tance to vancomycin (1,2). The use of vancomycin is
hypothesized to promote the development or transmission of
this resistance (3,4). Restrictive guidelines have therefore
been disseminated for the use of vancomycin or teicoplanin,
another glycopeptide agent (5). These guidelines include a
recommendation against the routine use of vancomycin as
perioperative antibiotic prophylaxis for surgical site infec-
tions.
However, vancomycin is preferred for preventing infec-
tions caused by methicillin-resistant Staphylococcus aureus
(MRSA) or methicillin-resistant coagulase-negative staphy-
lococci. This is the rationale for recommending vancomycin
prophylaxis when the risk for infection from methicillin-
resistant pathogens is high (6-11), although no guideline has
made a clear statement on when to use this alternative.
Since antibiotics are commonly used for prophylaxis, liberal
interpretation of the prophylaxis guidelines will clearly jeop-
ardize efforts to limit the use of vancomycin. Vancomycin is
also more expensive to purchase and administer than cepha-
losporins. 
To inform both the clinical and public policy debate with
respect to the optimal prophylaxis regimen, we conducted a
cost-effectiveness analysis to compare the short- and long-
term consequences of using vancomycin and cefazolin as
first-line perioperative prophylaxis. We focused on patients
who underwent coronary artery bypass graft surgery
(CABG) because this is a large, relatively homogeneous pop-
ulation with substantial risk for serious surgical site infec-
tion (12,13).
Methods
Cost-Effectiveness Analysis
We developed a decision-analytic model (Figure 1) to cal-
culate the clinical benefits and costs associated with alterna-
tive strategies for antibiotic prophylaxis in a hypothetical
cohort of 10,000 patients undergoing CAGB surgery. The
three strategies evaluated were 1) no prophylaxis; 2) routine
cefazolin, reserving vancomycin for those with a history of
allergic reaction to beta-lactam antibiotics; and 3) routine
vancomycin. In the base-case analysis, we adopted a payer
perspective and included clinical outcomes and direct medi-
cal costs in the 3 months after surgery. Clinical outcomes
included deep and superficial surgical site infections, as well
as hospital deaths. 
We also conducted a reference case analysis, as recom-
mended by the Panel on Cost-Effectiveness in Health and
Medicine (14), which assumed a societal perspective and
relied on a longer time horizon. The reference case was a 65-
year-old man undergoing CABG surgery for stable multives-
sel coronary heart disease. A state-transition model incorpo-
rated the lifetime probability of death, myocardial infarction,
angina, or asymptomatic coronary artery disease following
CABG surgery (15,16) to estimate life expectancy, quality-
adjusted life expectancy, and total lifetime costs. Future
costs and benefits were discounted at an annual rate of 3%.
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To conduct the cost-effectiveness analysis, the three
strategies were ranked by increasing effectiveness; those
that cost more but were less effective than an alternative
strategy were eliminated by strong dominance. When one
strategy was more effective but more costly, an incremental
cost-effectiveness ratio was calculated by dividing the addi-
tional cost of this specific strategy by its additional clinical
benefit, compared with the next least expensive strategy. We
conducted uni- and multivariate sensitivity analyses to
assess the stability of the results in the face of plausible vari-
ation in the underlying parameter estimates. All analyses
were performed by using DATA 3.5 (TreeAge Software, Inc,
Williamstown, MA).
Clinical Data
Table 1 summarizes the parameter estimates and their
plausible ranges. We assumed that antibiotics used to pre-
vent surgical site infection were partially protective only
against infections caused by susceptible bacteria. Vancomy-
cin-susceptible bacteria included all gram-positive organ-
isms except vancomycin-resistant enterococci. Cefazolin-
susceptible bacteria included aerobic gram-positive organ-
isms (except enterococci, MRSA, and methicillin-resistant
coagulase-negative staphylococci) as well as some aerobic
gram-negative bacteria. We based the proportion of surgical
site infections attributed to specific causative organisms on
microbiologic data from two published studies of patients
undergoing CABG surgery, most of whom received a first-
generation cephalosporin for prophylaxis (12,13).
The efficacy of antibiotic prophylaxis in patients under-
going CABG surgery is difficult to quantify directly since the
only available placebo-controlled studies were terminated
early because significantly better outcomes occurred in the
patients assigned to prophylaxis compared with controls
(34,35). Therefore, we assumed a relative risk of 0.4 for a
surgical site infection in patients who received antibiotic pro-
phylaxis compared with those who did not, which corre-
sponds to the highest effectiveness of antibiotic prophylaxis
within the range of results from completed placebo-con-
trolled studies in clean surgical procedures other than CABG
surgery (18-23). We used data on the incidence of surgical
site infections among patients receiving cefazolin from five
surveillance programs in university-affiliated hospitals in
Boston (17). By assuming that patients who received either
cefazolin or vancomycin shared the same relative risk of 0.4
of developing a surgical site infection due to a susceptible
organism, compared with patients who did not receive pro-
phylaxis, we were able to estimate the incidence of surgical
site infections for each strategy. We used data from the
National Nosocomial Infection Surveillance System (26) to
estimate the proportion of surgical site infections caused by
antibiotic-resistant organisms. We recognize that the inci-
dence of surgical site infections caused by antibiotic-resis-
tant organisms varies from one institution to another, and
therefore varied the resistance pattern over a wide range in
sensitivity analysis.
We assumed that 10% of patients had a history of
allergy to beta-lactam antibiotics (27). The incidence of
adverse events secondary to vancomycin was based on data
from a prospective study in which vancomycin was used for
10 days (24). We adjusted these estimates to reflect the prob-
ability of toxicity with a 2-day prophylactic regimen by
assuming a linear relationship between the incidence of
adverse events and the duration of therapy. We assumed
that the incidence of adverse events was the same for cefazo-
lin and vancomycin, since several comparative prophylactic
studies have reported the toxicity profiles to be similar
(25,36,37). Death rates secondary to deep surgical site infec-
tion (12), and anaphylactic reaction to cefazolin (28) were
obtained from published studies. We then derived the deaths
associated with the surgical procedure and its noninfectious
complications by using data on all-cause hospital deaths fol-
lowing CABG surgery reported for the state of Massachu-
setts (29).
We estimated quality-adjusted life expectancy by apply-
ing quality weights to the health states representing death,
myocardial infarction, angina, or asymptomatic coronary
artery disease. These quality weights were obtained from the
Beaver Dam Health Outcomes Study, in which time trade-off
techniques were used to elicit utilities (38). We explored a
wide range of quality-weights for the temporary health
states reflecting a superficial or deep surgical site infection. 
Costs
To estimate the costs associated with surgical site infec-
tions and hospital deaths, we relied on published estimates
(30-33) and adjusted these to 1998 U.S. dollars by using the
medical care component of the consumer price indexes pub-
lished by the Bureau of Labor Statistics (39). These studies
used costs from a cost accounting system (30,32) or charges
Figure 1. Model of the decision tree.*
*CABG = coronary artery bypass graft surgery; Hx = history of;
MRSA = methicillin-resistant  Staphylococcus aureus; MRCNS =
methicillin-resistant coagulase-negative staphylococci; VRE = van-
comycin-resistant enterococci.Research
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Table 1. Model variablesa 
Variables Base case Plausible range References
Incidence of SSI
Superficial 0.08 0.02 – 0.12 (12,17)
Deep 0.04 0.01 – 0.06 (12,17)
Causative organisms (12,13)
Staphylococcus aureus 0.25 0.20 – 0.35
Coagulase-negative Staphylococci 0.25 0.20 – 0.35
Enterococci 0.05 0.02 – 0.15
Gram-negative bacteria 0.30 0.15 – 0.50
Relative risk of SSI caused by susceptible organisms
Vancomycin vs. no prophylaxis 0.4 0.20 – 0.80 (18-23)
Cefazolin vs. no prophylaxis 0.4 0.20 – 0.80 (18-23)
Incidence of antibiotic-related adverse events
Vancomycin 0.08 0.01 – 0.20 (24)
Cefazolin 0.08 0.01 – 0.20 (24,25)
Incidence of SSI due to resistant organisms     (26)
MRSA (% of all SSI due to S. aureus) 0.012 (0.40) 0 – 0.03
Methicillin-resistant CNS (% of all SSI due to CNS) 0.024 (0.80) 0 – 0.03
VRE (% of all SSI due to enterococci) 0.003 (0.15) 0 – 0.006
Incidence of SSI caused by cefazolin-susceptible gram-
negative bacteria (% of all SSI due to gram-negative 
bacteria)
0.01 (0.28) 0 – 0.036
History of allergy to beta-lactams 0.1 0.05 – 0.15 (27)
Probability of hospital death
Deep surgical site infection 0.082 0.01 – 0.10 (12)
Antibiotic allergic reaction 0.00002 (28)
Coronary artery bypass graft surgery-related events 0.036 0.01 – 0.1 (29)
Costs per case (US$)
Vancomycin 80 60 – 250 (24)
Cefazolin 24 10 – 50 (24)
Superficial SSI 8,000 3000 – 15,000 (30,31)
Deep SSI 36,800 10,000 – 50,000 (30,31)
Vancomycin-related adverse  event 107 20 – 1,000 (24)
Cefazolin-related adverse  event 107 20 – 1,000 (24)
Death 5,900 0 – 10,000 (32)
Multiplication factor for infections due to methicillin-
resistant organisms
1.13 0.9 – 2 (33)
Multiplication factor for infections due to VRE  1.5 0.9 – 3 b
aSSI = surgical site infection; MRSA = methicillin-resistant Staphylococcus aureus; CNS = coagulase-negative staphylococci; VRE: vancomycin-resistant enterococci.
bWe assumed that the cost of an infection caused by a vancomycin-resistant enterococcus was 50% greater than the cost of a comparable infection caused by a susceptible strain.Research
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converted to costs (31,33) as a proxy for direct medical costs.
We based the costs of prophylaxis-related adverse events on
a study of vancomycin (24) and assumed identical costs for
cefazolin-related adverse events. We assumed that both van-
comycin and cefazolin would be used for 48 hours, which
implies a total of 5 doses of 1 g of vancomycin or 6 doses of 1
g of cefazolin. Antibiotic costs were based on hospital phar-
macy acquisition costs, although we added the cost associ-
ated with perfusion for both antibiotics (24). A preparation
cost was added for vancomycin only, since cefazolin is avail-
able in bags ready for infusion.
We estimated the costs of follow-up care by extrapolat-
ing the 5-year follow-up medical care cost after CABG sur-
gery among patients included in the Bypass Angioplasty
Revascularization Investigation (40).
Results
Base Case
Table 2 shows the intermediate health outcomes and
costs associated with the three prophylactic strategies for a
hypothetical cohort of 10,000 patients undergoing CABG
surgery. With no prophylaxis, the model predicted 570 deep
surgical site infections, 1,141 superficial surgical site infec-
tions, and 405 all-cause hospital deaths. Prophylaxis using
routine cefazolin, reserving vancomycin for patients with a
history of beta-lactam allergy, resulted in 173 fewer deep
surgical site infections, 347 fewer superficial surgical site
infections, and 14 fewer deaths compared with no prophy-
laxis. Prophylaxis using routine vancomycin resulted in 29
fewer deep surgical site infections, 58 fewer superficial surgi-
cal site infections, and 3 fewer deaths, compared with rou-
tine cefazolin. Routine vancomycin use was also associated
with the lowest direct medical costs for a 3-month period and
cost $1,170,000 less than routine cefazolin strategy per
10,000 patients. Since the routine vancomycin strategy was
more effective and less costly, the strategy of routine cefazo-
lin was eliminated by strong dominance.
Sensitivity Analysis
A strategy of no prophylaxis was always less effective
and more costly than using prophylaxis. Ranking of the rou-
tine vancomycin and cefazolin strategies, both in terms of
costs and clinical outcomes, was not affected when the fol-
lowing parameters were changed over the plausible range
described in Table 1: deaths from all causes and surgical site
infection-related deaths; incidence of deep or superficial sur-
gical site infection; distribution of causative organisms; inci-
dence of prophylaxis-related adverse events; proportion of
patients with allergy to beta-lactam antibiotics; costs of cefa-
zolin, deep or superficial surgical site infections, death, or
prophylaxis-related adverse events. 
Results were most sensitive to changes in the cost of
vancomycin, efficacy of cefazolin and vancomycin in prevent-
ing surgical site infections, and prevalence of bacterial resis-
tance to antibiotics. If the acquisition and administration
cost of 5 doses of vancomycin exceeded a threshold of $215,
cefazolin was no longer dominated by vancomycin since rou-
tine vancomycin became more costly. Similarly, routine van-
comycin became more costly than routine cefazolin if
vancomycin prevented 18% fewer infections caused by sus-
ceptible organisms compared with cefazolin; if this difference
exceeded 25%, the routine vancomycin strategy was less
effective and more costly and was thus dominated by the
cefazolin strategy.
We explored the impact of different antibiotic susceptibil-
ity profiles, as might be observed in different hospitals, on
these results. Routine vancomycin remained the most effec-
tive and the least costly strategy independent of the preva-
lence of vancomycin-resistance in enterococci. Figure 2 shows
a three-way sensitivity analysis of the incidence of surgical
site infection caused by each of the following pathogens: an
MRSA; a methicillin-resistant coagulase-negative staphylo-
coccus; and a cefazolin-susceptible gram-negative bacteria.
For a given incidence of surgical site infection caused by
MRSA, each line represents the threshold combinations of
methicillin resistance in coagulase-negative staphylococci
and cefazolin susceptibility in gram-negative bacteria for rou-
tine vancomycin to be more cost-effective than routine cefazo-
lin. For example, in the base case, we assumed a 2.4 per 100
risk for infection caused by methicillin-resistant coagulase-
negative staphylococci and a 1.0 per 100 risk for surgical site
infection caused by cefazolin-susceptible gram-negative bac-
teria. Routine cefazolin was more cost-effective than vanco-
Table 2. Base-case analysis: clinical outcomes and costs for a hypothetical cohort of 10,000 patients undergoing coronary artery bypass graft surgery
Strategy
Deep 
SSI
Increm. 
deep 
SSIa
Superficial 
SSI
Increm. 
superficial 
SSIa
Hospital 
deaths
Increm. 
hospital 
deathsa
Deaths, 
SSI, or 
both
Increm. 
deaths, 
SSI, or 
both
Costs 
(x $1,000)
Increm. 
costs 
(x $1,000)a
No 
prophylaxis
570 - 1141 - 405 - 2,008 - 33,410 -
Routine 
cefazolin
397 - 173
b 794 - 347
b 391 - 14
b 1,506 - 502
b 24,530 - 8,880
b
Routine 
vancomycin
368 - 29b 736 - 58b 388 - 3b 1,423 - 83b 23,360 - 1,170b
SSI = surgical site infection; increm = incremental.
aRoutine cefazolin compared with no prophylaxis; routine vancomycin compared with routine cefazolin.
bNegative incremental numbers of infections or deaths represent the numbers of infections or deaths averted; negative incremental costs represent costs
saving.Research
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mycin only when the incidence of surgical site infections
caused by MRSA was lower than 0.09 per 100, which repre-
sents 3% of the infections caused by S. aureus.
The impact of different patterns of antimicrobial resis-
tance on the incremental cost-effectiveness ratio associated
with routine vancomycin compared with routine cefazolin is
shown in Figure 3. This ratio represents the added cost of
using vancomycin divided by the additional clinical benefits
provided by vancomycin (i.e., additional death or surgical
site infection averted), compared with the next least expen-
sive strategy. For example, in a hypothetical hospital where
MRSA caused surgical site infections in 1% of the patients
undergoing CABG surgery, methicillin-resistant coagulase-
negative staphylococci in 2.5%, and cefazolin-susceptible
bacteria in 1.5%, the incremental cost-effectiveness ratio for
routine vancomycin was $10,237 per additional infections or
death averted, compared with routine cefazolin.
Reference Case
In a hypothetical cohort of 65-year-old men undergoing
CABG surgery, quality-adjusted life expectancy was 8.312
quality-adjusted life-years, and per person lifetime costs
were $62,892 in the absence of prophylaxis (Table 3). A strat-
egy of prophylaxis with routine cefazolin was $876 less costly
and provided an additional 0.023 quality-adjusted life years
compared with no prophylaxis. The most effective strategy,
prophylaxis with routine vancomycin, saved an additional
$103 compared with cefazolin and therefore dominated a
strategy of routine cefazolin.
Similar to the results for the base case, our reference case
results were most sensitive to estimates for the acquisition
and administration cost of vancomycin; the efficacy of vanco-
mycin and cefazolin in preventing surgical site infections; and
the prevalence of bacterial resistance to antibiotics.
Discussion
In the base-case analysis, a strategy of routine vancomy-
cin prophylaxis in the overall population of CABG patients
was more effective than a strategy of routine cefazolin, since
it prevented more surgical site infections or deaths caused by
methicillin-resistant staphylococci or enterococci. Routine
vancomycin was also less costly than cefazolin, an advantage
that was offset neither by higher acquisition and administra-
tion costs nor by the absence of protection against gram-neg-
ative bacteria. Although these results were dependent on the
prevalence of antibiotic resistance in the causative organ-
isms, the range of circumstances in which a strategy of rou-
tine cefazolin was either more effective or less costly than
vancomycin was narrow, restricted to situations in which
MRSA represented no more than 3% of all S. aureus.
In the reference case analysis, a strategy of routine van-
comycin was also more effective and less costly than a strat-
egy of routine cefazolin. Because of a lack of available data,
we were not able to quantify the precise contribution of rou-
tine vancomycin use to the development of vancomycin-resis-
tance in gram-positive organisms. However, we did conduct
sensitivity analyses to explore the impact of a decrease in
efficacy of vancomycin on our results. Estimating the future
economic consequences that might be associated with the
development of vancomycin resistance is more difficult. Anti-
biotic resistance, described in economic terminology as an
externality associated with the use of antimicrobials (41), is
an effect of antimicrobial use that is unlikely to be felt by
either the patient or the provider. We know from experience
with vancomycin-resistant enterococci that surveillance pro-
grams, isolation of colonized patients, and treatment of infec-
tions that resist most existing antibiotics increase costs.
Figure 2. Three-way sensitivity analysis of the incidence of surgical
site infection (SSI) caused by methicillin-resistant Staphylococcus
aureus  (MRSA); methicillin-resistant coagulase-negative staphylo-
cocci; or cefazolin-susceptible gram-negative bacteria.  The lines
show the incidence of infection caused by methicillin-resistant Sta-
phylococcus aureus necessary for routine cefazolin prophylaxis to be
more cost-effective than routine vancomycin (0.09%, 0.6%, 1.2%, and
1.8%). For a particular line, points to the lower right indicate that
routine vancomycin is more cost-effective; points to the upper left
indicate that routine cefazolin is more cost-effective. The dotted line
represents the example cited in text. SSI = surgical site infection;
MRSA = methicillin-resistant Staphylococcus aureus; CNS = coagu-
lase-negative staphylococci; GNB = gram-negative bacteria.
Figure 3. Determination of the incremental cost-effectiveness ratio
of the routine vancomycin strategy relative to the routine cefazolin
strategy, according to bacterial resistance pattern. To determine the
incremental cost-effectiveness ratio: 1) Place percent incidence of
surgical site infection caused by methicillin-resistant  Staphylococ-
cus aureus on the a axis; 2) Place percent incidence of surgical site
infection caused by methicillin-resistant coagulase-negative staphy-
lococci on the b axis; 3) Draw a line between these 2 points. This line
crosses the c axis at a point x; 4) Place percent incidence of surgical
site infection caused by cefazolin-susceptible gram-negative bacteria
on the scale d; 5) Draw a line passing through this point and the
point x on the c axis. If this line crosses the e axis between the two
zones of dominance, the incremental cost-effectiveness ratio can be
red (in thousands of dollars per additional death or surgical site
infection averted). The dotted lines represent the example cited in
text.Research
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Similarly, the spread of vancomycin resistance in highly
pathogenic species such as S. aureus could have substantial
clinical and economic consequences. When data become
available to document and quantify the relationship between
the routine use of vancomycin and vancomycin resistance,
we will be able to better describe the trade-off between the
short-term benefits to individual patients and the long-term
consequences to society at large. However, there are similar
uncertainties with respect to the consequences of routine
cefazolin, which selects for MRSA and cefazolin-resistant
gram-negative organisms and is a recognized risk factor for
the acquisition of infection caused by vancomycin-resistant
enterococci (4).
We believe our decision not to model the relationship
between antibiotic prophylaxis and resistance had a limited
impact on our results. For instance, routine vancomycin
would still be more effective and less costly than routine
cefazolin if all enterococci were resistant to vancomycin
because of the small proportion of surgical site infections
caused by enterococci after CABG surgery. The spread of
vancomycin resistance in staphylococci, however, would
impact the model more substantially. We therefore simulated
a hypothetical scenario in which prevalence of vancomycin
resistance in enterococci would continue to increase by about
2% per year, as reported in U.S. hospitals from 1989 through
1997 (4), and in which the same trend would be observed in
staphylococci (data not shown). We arbitrarily assumed that
vancomycin prophylaxis, but not cefazolin prophylaxis,
would accelerate this trend by 50%. Under these circum-
stances, routine vancomycin would no longer be less costly
than routine cefazolin after 6 years and would also become
less effective after 13 years. Although such a simulation
addresses the issue of future resistance crudely and incom-
pletely, it illustrates how speculative it would be to model
this evolution, given the current lack of knowledge about gly-
copeptide resistance in staphylococci.
The conclusions of this analysis were not meaningfully
influenced by uncertainty around the model parameters,
according to sensitivity analyses conducted over a wide
range of plausible values. Other than the influence of suscep-
tibility patterns discussed above, the results were sensitive
only to large variations of the price of vancomycin and to the
relative effectiveness of the two prophylactic drugs. This last
aspect is a limitation of the study due to insufficient data.
The effectiveness of cefazolin may have been underestimated
if cefazolin has some effect against methicillin-resistant sta-
phylococci when the inoculum is small, as may be the case
during surgery. We can also speculate that a large proportion
of methicillin-resistant organisms are acquired after sur-
gery; perioperative antibiotic prophylaxis may not prevent
infections caused by these organisms. We are not aware of
data supporting this hypothesis, however. We assumed that
both vancomycin and cefazolin had the same preventive effi-
cacy against susceptible organisms. However, vancomycin
would no longer be the best option if it were 18% less effec-
tive than cefazolin in preventing infections caused by suscep-
tible organisms. Beside uncertainty regarding the relative
intrinsic effectiveness of the two drugs, this effectiveness
may be differently affected by suboptimal use such as wrong
timing or wrong dose, because of distinct pharmacokinetic
characteristics. In general, vancomycin’s longer half-life in
serum would be expected to make it more tolerant than cefa-
zolin if delays occur between administration of prophylaxis
and initiation of surgery. Finally, we did not include patient
time costs in the reference case analysis. However, their
inclusion would only have increased the estimated benefit
associated with preventing infections. 
These results underscore the importance of using a peri-
operative prophylaxis regimen with reasonable activity
against gram-positive organisms. Failure to provide patients
undergoing CABG with an acceptable perioperative prophy-
laxis regimen is an example of a medical error; in the aggre-
gate, these errors have been recognized to negatively affect
clinical outcomes and to impose a large burden on health
resources (42). Because the circumstances in which perioper-
ative prophylaxis must be administered are highly struc-
tured, development of systems to achieve near-perfect
compliance could be feasible for the health- care delivery sys-
tem. The motivation for making this a priority is particularly
strong because prophylaxis was estimated to save at least
$900 per person. The strategy of no prophylaxis was always
associated with both higher costs and a greater number of
deaths and surgical site infections than either of the two
alternative prophylactic strategies. In fact, the cost attrib-
uted to failure to provide prophylaxis may have been under-
estimated, since we assumed that the risk reduction was
similar to that observed in other clean surgical procedures
(18-23).
Approximately 366,000 CABG operations are performed
yearly in the United States (43). Using the best data cur-
rently available and considering clinical outcomes to individ-
ual patients, our model predicts that routine vancomycin
Table 3. Reference case analysis: quality-adjusted life expectancy and lifetime costs for a 65-year-old man undergoing coronary artery bypass
graft surgery
Strategy Total costs ($)
Incremental costsa 
($) QALYs Incremental QALYs
a
Incremental cost-
effectiveness ratio
a
No prophylaxis 62,892 - 8.312 - -
Routine cefazolin 62,016 - 876
b 8.335 0.023 Dominated
c
Routine vancomycin 61,913 - 103
b 8.339 0.004 Cost saving
QALYs = quality-adjusted life years.
aRoutine cefazolin compared with no prophylaxis; routine vancomycin compared with routine cefazolin.
bNegative incremental costs represent cost savings.
cA dominated strategy is one that costs more and is less effective than an alternative strategy.Research
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would prevent 110 deaths and 3,184 surgical site infections
compared with routine cefazolin. Under conditions similar to
those in our base case, the routine vancomycin strategy
would also save $43 million nationwide. Similar conclusions
are to be expected from the analysis of clean surgical proce-
dures other than CABG, since most surgical site infections
are caused by staphylococci in these settings. Because data
are insufficient to provide information about the potential
downstream societal consequences of routine vancomycin
use on the development of vancomycin resistance, we are
reluctant to recommend the universal routine use of vanco-
mycin. However, the incremental clinical benefits and cost
savings associated with routine vancomycin compared with
routine cefazolin for perioperative prophylaxis in CABG sur-
gery provide an estimate of the magnitude of benefits that
would need to result, at least for society at large, from slow-
ing the emergence of vancomycin resistance by restricting its
use. We recommend that immediate priority be given to
studies that will inform the impact of vancomycin use on the
development of resistance in gram-positive organisms.
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